What the evidence really says about GLP‑1 weight‑loss drugs
A calm, evidence‑based look at GLP‑1 medicines: how they work, side‑effects, weight regain and what you can do this week.
A new class of appetite‑suppressants has moved from diabetes clinics to the mainstream, and headlines are full of claims about miracle weight loss, glowing skin and even cancer protection. The reality is messier – the drugs are powerful, they have predictable side‑effects, and they work best when paired with sensible diet and exercise.
According to The Guardian, the conversation around GLP‑1 medicines has become a mix of fact and folklore. Below we unpack the biology, compare the drugs with other weight‑management options, and flag the gaps that still need research.
How GLP‑1 drugs mimic a natural hormone
GLP‑1 (glucagon‑like peptide‑1) is a gut hormone released by L‑cells when food enters the intestine. In a healthy person the hormone spikes for a few minutes, slowing gastric emptying and signalling the brain that we are full. The drugs are synthetic versions of this peptide, but they are engineered to stay in the bloodstream for days rather than minutes. If a natural burst is a sparkler, a weekly injection is a bonfire that keeps the appetite‑suppressing signal alive for up to a week.
Because the signal persists, people feel fuller faster and eat less – studies quoted in the article show reductions of up to 40 % in daily calories. The effect is not a complete shutdown of hunger; once the drug level falls, the appetite returns.
Side‑effects that matter in everyday life
The most common complaints are nausea, constipation, diarrhoea, bloating and vomiting. They tend to appear during the dose‑escalation phase and usually improve as the body adapts. Simple measures – smaller meals, extra fluids and a gradual increase in fibre – can blunt the worst of these symptoms. However, the drugs also slow gastric emptying so markedly that eating beyond the point of fullness can cause discomfort; patients are advised to stop eating the moment they feel satied.
A less obvious risk is reduced fluid intake. Because appetite is dampened, people may drink less, especially if nausea is present. Dehydration can exacerbate constipation and reflux, so a conscious effort to sip water and include water‑rich foods (cucumbers, soups, smoothies) is essential, particularly on the day the injection is given.
Nutrient shortfalls and muscle loss
When you cut calories dramatically, the quality of the remaining diet becomes critical. The article notes that users of GLP‑1 drugs can become deficient in vitamin D, vitamin B12, iron, calcium and protein if their baseline diet was already low in these nutrients. For someone who already eats a balanced diet, eating less simply means a lower absolute intake of each nutrient, but the risk of deficiency is still higher.
Weight loss inevitably includes some loss of lean tissue. Current evidence suggests up to 40 % of the weight lost on GLP‑1 therapy may be lean mass (muscle, bone, connective tissue). Preserving muscle therefore requires two strategies: a protein‑rich diet (about 1.2–1.5 g of protein per kilogram of body weight per day) and resistance training at least three times a week. Without these, the loss of muscle can undermine long‑term metabolic health and functional strength.
What happens when the medication stops?
Obesity is a chronic, relapsing condition. When GLP‑1 therapy is withdrawn, appetite returns to its pre‑treatment level and most people regain weight. One Oxford study cited in the source found that, on average, participants returned to their original weight within two years after stopping the drug. The figure quoted by the experts – about 60 % of the lost weight – aligns with that observation.
The practical implication is that, for many, GLP‑1 medicines become a long‑term therapy, similar to antihypertensives or statins. The decision to stay on the drug therefore hinges on a risk‑benefit assessment that includes cost, side‑effect tolerance and personal health goals.
Comparing GLP‑1 therapy with other weight‑loss options
| Option | Typical weight loss (6 months) | Need for ongoing treatment | Main side‑effects | Cost (UK, 2024) |
|---|---|---|---|---|
| GLP‑1 drugs (e.g., semaglutide) | 10–15 % of body weight | Usually lifelong to maintain loss | Nausea, constipation, dehydration, rare hair loss | £80‑£120 per month (NHS may fund for qualifying obesity) |
| Very‑low‑calorie diet (800 kcal/day) | 5–10 % | Short‑term, high relapse risk | Nutrient deficiencies, gallstones | £0‑£200 (dietitian) |
| Bariatric surgery (gastric bypass) | 20–30 % | Usually permanent, occasional revisions | Surgical complications, malabsorption | £5 000‑£10 000 (NHS funded for BMI ≥ 40 or ≥ 35 with co‑morbidities) |
| Structured lifestyle programme (NHS "Weight Management Service") | 3–5 % | Ongoing support required | Minimal | Free (NHS) |
The table shows that GLP‑1 drugs sit between intensive diet programmes and surgery in terms of efficacy, but they require a commitment to a medication schedule and monitoring of side‑effects.
Trade‑offs and who should care
The primary trade‑off is potency versus permanence. A GLP‑1 drug can deliver rapid, clinically meaningful weight loss without the surgical risks, yet it creates a pharmacological dependency. People with type 2 diabetes, for whom the drug also improves glycaemic control, may find the dual benefit compelling. Conversely, someone seeking a short‑term cosmetic change (e.g., before a wedding) may expose themselves to muscle loss and rebound weight gain without lasting health benefits.
Who gains? Patients with obesity‑related co‑morbidities (type 2 diabetes, hypertension, sleep apnoea) who meet NHS eligibility criteria can access the drugs at no personal cost, potentially improving multiple health markers. Who loses? Individuals without medical supervision who self‑source the medication, use it for aesthetic purposes, or ignore the need for nutrient‑dense meals and resistance training may experience the same weight loss but at the expense of lean mass, hydration and long‑term metabolic stability.
Uncertainties and what the source leaves open
Several claims remain tentative. The notion that GLP‑1 drugs reduce the risk of certain cancers or cardiovascular events is supported by observational data, but separating the drug’s direct effect from the effect of weight loss is still a work in progress. Mental‑health benefits are described as "pretty thin" – the evidence for reduced anxiety or depression is not yet robust, and ongoing trials may clarify the picture.
Anecdotal reports of "Ozempic breath" and sulphur‑smelling burps have plausible mechanistic explanations (dry mouth, delayed gastric emptying fostering bacterial fermentation), yet no epidemiological studies have quantified their prevalence. Hair loss, described as telogen effluvium, appears reversible but its incidence and severity across different doses are not well documented.
In practice, the biggest unknown is the long‑term adherence landscape. If a patient stops the drug after a year of success, the weight‑regain trajectory will depend on lifestyle habits built during treatment. Without structured follow‑up, the risk of returning to a higher‑risk weight is substantial.
A realistic step you can take this week
If you are already on a GLP‑1 prescription, schedule a brief nutrition review this week – either with your GP, practice nurse, or a registered dietitian. Aim to:
- Confirm you are meeting at least 1.2 g of protein per kilogram of body weight each day (e.g., a 70 kg adult should aim for ~84 g of protein).
- Add a 15‑minute resistance‑training routine, such as body‑weight squats, push‑ups or resistance‑band rows, three times before your next injection.
- Track fluid intake; a simple goal is 1.5 L of water plus hydrating foods per day.
These three actions address the most common pitfalls – nutrient shortfalls, muscle loss, and dehydration – and set a foundation for sustainable results.
